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Abstract 
Objective. To review the implications of a local over-production of tumor necrosis factor-α 
for the pathogenesis and treatment of complex regional pain syndrome. 
Background. Elevated local production of tumor necrosis factor-α contributes to prolonged 
inflammation in the early stages of complex regional pain syndrome. Consequences could 
include hypoxia and necrosis of local tissues. 
Method. We conducted a review of papers published since 2000 on tumor necrosis factor-α 
in complex regional pain syndrome.  
Results. We propose that exaggerated local inflammation, subsequent inhibition of N-type 
calcium channel currents in sympathetic vasoconstrictor neurons and reduced sympathetic 
neurotransmitter release from perivascular terminals disrupt sympathetic cutaneous 
vasoconstrictor activity in complex regional pain syndrome. The resultant microvascular 
disturbance could exacerbate inflammation in the affected limb. In addition, an under-active 
cholinergic anti-inflammatory pathway might lead to overproduction of tumor necrosis 
factor-α. The results of large, randomized controlled treatment studies that test the efficacy of 
selective anti-tumor necrosis factor-α drugs in complex regional pain syndrome are not yet 
available.  However, numerous small-scale studies and case reports indicate that anti-
inflammatory drug treatments that directly or indirectly target tumor necrosis factor-α 
ameliorate pain and other symptoms in some cases.   
Conclusions.  An exaggerated inflammatory cytokine cascade may contribute to sensory and 
autonomic disturbances in complex regional pain syndrome. Further investigation of anti- 
tumor necrosis factor-α therapy as a cost-effective treatment option for this devastating 
disease is required. Whether increased activity in the cholinergic anti-inflammatory pathway   3 
provides therapeutic benefits for complex regional pain syndrome also warrants further 
investigation. 
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Introduction 
Complex regional pain syndrome (CRPS) involves sensory disturbances such as spontaneous 
stabbing and burning pain, exaggerated stimulus-evoked pain and impaired tactile 
discrimination in the affected limb; autonomic nervous system dysfunction associated with 
vascular and sweating abnormalities; trophic changes in skin, hair, nails and bone; motor 
disturbances resulting in weakness, tremor and dystonia; and persistent edema in the CRPS-
affected extremity [1-10]. Symptoms can develop after minimal direct injury to peripheral 
nerves (termed CRPS type 1), or may be associated with major nerve trunk injury (termed 
CRPS type 2).  
Potential CRPS-inciting events include crush injury, compression injury, ischemia-
reperfusion, fracture, contusion (soft tissue injury), sprain, strain, stroke, shock, hypoxia, 
cardiac ischemia, surgery (usually involving the distal part of an extremity such as carpal 
tunnel release), invasive procedures (venipuncture, intramuscular injection) and overly tight 
casting or immobilisation.  These events may trigger an inflammatory cascade that results in 
prolonged and excessive ‘sterile’ inflammation and, in some unfortunate cases, the 
development of CRPS [1-13].  Nerve and tissue injury activates mast cells, macrophages and 
other tissue-resident cells, resulting in the release of inflammatory mediators such as tumor 
necrosis factor-α (TNF) and histamine and the recruitment of circulating neutrophils and 
monocytes [14].  Excess local TNF production may then play a key role in perpetuating an 
exaggerated inflammatory cascade that, if not resolved, triggers painful CRPS.   
To explore this question, we conducted a review of papers listed in PubMed since 2000 on 
TNF in CRPS, supplemented by targeted searches using the Google search engine. In 
addition, references by key authors and those cited in relevant papers were traced.    
This paper begins by providing an overview of the role of TNF in CRPS. We then examine 
the possibility that excess local TNF might not only mediate chronic inflammation and pain   5 
in CRPS but could also contribute to sympathetic dysfunction and associated vascular 
deficits. We subsequently review the role of the parasympathetic nervous system in CRPS – 
specifically the prospect that an under-active cholinergic anti-inflammatory pathway 
increases the likelihood of TNF over-production and chronic pain. Finally, we examine the 
efficacy of drugs that directly or indirectly target TNF in CRPS.  
TNF in animal models of CRPS  
As a master cytokine, TNF has a lead role in activating an inflammatory cytokine cascade 
that involves release of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6 and IL-8 
[15-18].  Additionally, TNF plays an important part in hypernociception during antigen-
induced inflammation [19] and acts on sensory neurons to induce hyperalgesia [20].  
Increased TNF levels may also lead to up-regulation of the voltage-gated sodium channels 
Nav1.3 and Nav1.8 in uninjured dorsal root ganglion neurons following neuronal injury, 
hence implicating not only injured but also uninjured neurons in neuropathic pain [15,18,21-
26].  
In a rat model of CRPS type 1 involving distal tibia fracture, increased production of TNF 
and the inflammatory cytokine cascade was detected in the hindpaw skin of the fractured 
limb [27-30].  Contributing to this response was substance P-mediated mast cell 
degranulation, which increased IL-1β release and contributed to nociceptive sensitization 
[31].  In addition, tibia fracture led to keratinocyte activation and proliferation, and 
heightened expression of TNF and other inflammatory mediators in the fractured hindpaw 
[30]. Conversely, the cytokine inhibitor pentoxifylline decreased cytokine expression and 
CRPS-like symptoms in this model [32].   
The chronic post-ischemia pain (CPIP) model of CRPS involves an ischemia-reperfusion 
injury induced by a tight tourniquet on the hind limb of anaesthetized rats for three hours.    6 
Removal of the tourniquet results in immediate blood reperfusion, hyperemia, plasma 
extravasation and edema.  CPIP animals demonstrate spontaneous pain, hyperalgesia and 
allodynia in the affected paw and spread of symptoms to the uninjured hindpaw [4].  This 
model also involves sympathetic dysfunction, increased activity of the DNA transcription 
factor nuclear factor κB (NFκB) that triggers production of TNF, and high levels of TNF and 
other pro-inflammatory cytokines.  The ischemia-reperfusion injury evokes microvascular 
disturbances that result in poor tissue perfusion, chronic tissue ischemia and tissue damage 
with reduced small-diameter nerve fibre endings in the skin and abnormal capillary 
endothelial cells in skeletal muscle and tibial nerve [4,33-35].  Preventing the translocation of 
NFκB into the nucleus inhibits the production of TNF, IL-1β and cyclooxygenase-2 in 
macrophages and other immune cells, and impedes the development of hyperalgesia in 
inflammatory and neuropathic pain models [36-39].  Inhibition of NFκB also prevents TNF-
mediated expression of cell adhesion molecules in endothelial cells, thereby reducing the 
extravasation of circulating leukocytes and attenuating inflammation [40]. Pyrrolidine 
ditiocarbamate, a NFκB antagonist, and free radical scavenger drugs such as N-acetylcysteine 
and Tempol that reduce NFκB activation [41-43], decrease signs of hyperalgesia in CPIP rats 
[4,34,44]. Thus, NFκB and TNF appear to be pivotal in this model of CRPS.   
The TNF receptor 1 is involved in thermal hyperalgesia and mechanical allodynia evoked by 
chronic constriction injury in mice [45].  Neutralizing antibodies to TNF reduce pain 
behaviours both in this model and after partial sciatic nerve transection, possibly due to 
decreased TNF or nerve growth factor in the injured nerve or reduced anterograde transport 
of TNF in the intact and injured nerves [46,47].  Etanercept, a selective anti-TNF drug, 
reduces hyperalgesia in the chronic constriction injury model [48] and significantly decreases 
mechanical allodynia in the spinal cord injury model [49].     7 
Together, these studies indicate that TNF is an important mediator of pain and inflammation 
in a diverse range of neuropathic pain models, both in studies with minimal direct injury to 
peripheral nerves that attempt to replicate CRPS type 1, and also after direct injury to 
peripheral nerves (CRPS type 2).  
The role of TNF in CRPS patients 
An exaggerated posttraumatic ‘sterile’ inflammatory response that includes a persistently 
elevated pro-inflammatory cytokine profile, delayed resolution of the inflammatory cascade 
and depressed anti-inflammatory cytokine expression may contribute to the onset and 
maintenance of CRPS [17,50-52].  In an elegant study by Üçeyler et al. [50], 42 CRPS 
patients (median disease duration 12 weeks; range 3 to 70 weeks) were found to have a 
higher pro-inflammatory cytokine profile than age- and gender-matched healthy controls 
(n=34).  Specifically, CRPS patients had greater pro-inflammatory TNF and IL-2 serum 
levels and lower anti-inflammatory IL-4 and IL-10 mRNA serum levels than controls.  
Notably, IL-10 (an anti-inflammatory cytokine) could not be detected in 27 of 42 CRPS 
patients, whereas pro-inflammatory IL-2 was absent in 32 of 34 controls [50]. Findings from 
similar studies have confirmed that the early stages of CRPS are characterized by increased 
pro-inflammatory cytokine activity [6,7,53,54], particularly TNF and IL-6 [55].   
It is becoming increasingly clear that local, as opposed to systemic, inflammation is likely to 
contribute significantly to CRPS [17,56]. In a study based on 3-phase bone scintigraphy, TNF 
overproduction was detected in the CRPS-affected hands of three early-stage CRPS patients 
but not in the contralateral hands or in patients with chronic CRPS [57].  In another study that 
involved assessing both skin and serum TNF levels, skin punch biopsies and blood samples 
were taken from 10 patients with osteoarthritis, ten with acute traumatic upper limb bone 
fracture, and from the affected limb of another ten patients with CRPS type 1 [17]. TNF 
levels were greater in skin samples from CRPS patients than in skin punch biopsies from the   8 
other patient groups, whereas serum TNF was similar in patients with osteoarthritis and 
CRPS. Together, these findings signify the importance of locally-produced TNF in the 
pathogenesis of CRPS. From a practical point of view, the findings also suggest that skin 
punch biopsies could be used as a minimally invasive diagnostic tool to quantify local TNF 
levels in the CRPS-affected limb [17]. 
In association with local leukocyte accumulation [58], the elevated local production of TNF 
may mediate persistent ‘sterile’ inflammation and tissue damage in the acute CRPS-affected 
limb [3,59-63].  For example, in a study involving 66 primarily acute-stage patients, higher 
local TNF and IL-6 levels were observed in most of the induced skin blisters [64].  On the 
other hand, IL-6 levels in blister fluids of chronic CRPS patients (n=12; median duration=6 
years) were significantly reduced compared with levels shortly after CRPS onset, and TNF 
levels also trended down [65]. Together, these findings suggest that increased TNF, IL-6 and 
other pro-inflammatory agents are associated with tissue damage, necrosis and pain during 
the early stages of CRPS, whereas additional mechanisms may contribute later on.  
How might locally-increased TNF contribute to tissue damage and necrosis in CRPS? 
TNF can stimulate both inflammation and cell death [66]. Thus, poor resolution of a TNF-
induced inflammatory cytokine cascade might evoke an exaggerated posttraumatic ‘sterile’ 
inflammatory response that contributes to symptoms of CRPS [50-52] (Figure 1).  
Specifically, excess TNF and other inflammatory cytokines may result in local tissue damage 
that includes necrosis of sympathetic cutaneous vasoconstrictor and other small-diameter 
nerve fibers, mitochondrial dysfunction, abnormal endothelial cell activity, poorly-formed 
capillaries and dysfunctional capillary outgrowth, pericyte damage and skeletal muscle fibre 
losses in the CRPS-affected limb [67-69].  In turn, hypoactive or degenerating sympathetic 
efferent fibres could prevent blood from being diverted from arterioles into local capillary 
beds in CRPS-affected tissue, thereby limiting oxygen and nutritive supply and delaying   9 
waste removal. While the affected extremities of ‘warm limb’ patients may appear flushed 
and hyperemic, the tissues below the skin could actually be ‘paradoxically ischemic’ 
[67,70,71].  Indeed, increased skin lactate in CRPS-affected limbs is consistent with tissue 
ischemia [72].  Local tissue damage could contribute to the maintenance of many CRPS 
symptoms including neuropathic pain, autonomic dysregulation, motor dysfunction and 
edema [3,13,67,68,70,71,73-75].   
Prolonged production of TNF by macrophages and other immune cells may mediate 
persistent ‘sterile’ secondary inflammation, pain, severe tissue damage and necrosis [76].  
Necrosis involves rapid cell membrane lysis and the passive release of intracellular contents 
including high mobility group box-1 (HMGB1) protein from the nuclei of necrotic cells 
[77,78].  HMGB1 interacts with Toll-like receptor 4 expressed by macrophages, 
activates NFκB and stimulates further production of TNF and other pro-inflammatory agents, 
leading to the activation of dendritic and endothelial cells [78-80].  A vicious circle involving 
extravasation of neutrophils and monocytes from the circulation, activation of macrophages, 
TNF production and an exaggerated inflammatory cytokine cascade could then result in 
persistent and excessive ‘sterile’ inflammation in CRPS-affected limbs.  The ongoing passive 
release of excess HMGB1 by necrotic cells may further exacerbate tissue damage and 
necrosis [81-84] (Figure 1).   
Does TNF-mediated inhibition of the N-Type calcium current contribute to impaired 
sympathetic cutaneous vasoconstriction in CRPS?  
Whole-body cooling and warming provokes three distinct patterns of cutaneous blood flow in 
CRPS patients: increased blood flow and warmth in the symptomatic limb irrespective of 
body temperature, consistent with impaired sympathetic cutaneous vasoconstriction; 
decreased flow and coolness in the symptomatic limb irrespective of body temperature; or an 
intermediate type where the symptomatic limb is warmer or cooler than the contralateral limb   10 
at different body temperatures [85,86]. The cold pattern is most common in CRPS patients 
with the longest duration of pain [87], possibly due to the development of adrenergic 
supersensitivity or up-regulation of vasoconstrictors such as endothelin-1 as the condition 
progresses [61,88,89].  
Reductions in venous concentrations of sympathetic neurotransmitters and their metabolites 
in the warm or cool CRPS-affected limb indicate that sympathetic neurotransmission is 
compromised in at least some patients [85,90-95].  This may be due to a combination of 
sympathetic denervation [67] and altered control of sympathetic neural activity [94,96-98]. 
Although much evidence points toward a central disturbance in regulation of autonomic 
activity in CRPS [85,93,97-100], a sympathetic deficit distal to the site of trauma may also 
contribute to local hypoxia and decreased nutritive supply in the CRPS-affected limb [101-
103].  In addition, animal models of neuropathic pain suggest that peripheral nerve injury 
triggers novel sympathetic neurite sprouting. Pathologic coupling between these sprouts and 
nociceptive neurons in the dorsal root ganglia and upper dermis may underpin 
sympathetically maintained pain [3,104-107].      
An additional mechanism involving excess local TNF production could disrupt sympathetic 
vasoconstrictor activity in the CRPS-affected extremity.  Normal N-type calcium channel 
function in sympathetic efferent fibres is essential for release of the vasoconstrictor 
neurotransmitters noradrenaline, ATP and neuropeptide Y [108,109].  In vitro studies have 
demonstrated that excess TNF stimulates the signaling of transcription factor NFκB, leading 
to reduced calcium entry into N-type calcium channels, selective inhibition of the N-type 
calcium channel current and decreased sympathetic neurotransmitter release from the 
perivascular terminals of postganglionic sympathetic neurons [110,111] (orange arrows in 
Figure 1).  Selective TNF-mediated inhibition of the N-type calcium channel current in   11 
sympathethic efferents is linked with Crohn’s disease and Guillain-Barré syndrome [110-
114], but whether this mechanism also contributes to CRPS has yet to be established.  
Does impairment of the cholinergic anti-inflammatory pathway play a role in CRPS? 
It is widely accepted that an autonomic imbalance that involves the sympathetic nervous 
system results in altered tissue perfusion and hyper- or hypohidrosis in CRPS. However, 
there is a paucity of research that investigates whether changes in parasympathetic activity 
also contribute to autonomic dysfunction or other disturbances in CRPS. Persistently 
impaired parasympathetic vagal outflow may contribute to cardiovascular disease [115-120], 
postoperative pain [121], fibromyalgia [122,123], chronic fatigue syndrome, postural 
orthostatic tachycardia syndrome [124,125], migraine [126], depression [127,128], 
inflammatory bowel disease [113,114] and various inflammatory autoimmune diseases 
(rheumatoid arthritis, systemic lupus, primary Sjögren syndrome, polymyalgia rheumatica 
and scleroderma) [129,130]. Whether vagal outflow is also compromised in CRPS warrants 
further investigation, as the efferent vagus nerve forms part of the cholinergic anti-
inflammatory pathway.  
An overview of the cholinergic anti-inflammatory pathway (Figure 2) 
Innate immune responses are regulated in various ways via humoral and neural pathways.  
The humoral pathway controls the release of hormones and cytokines via the hypothalamic-
pituitary-adrenal axis.  This pathway mediates systemic and local effects on target tissues via 
circulating anti-inflammatory hormones (corticosteroids, glucocorticoids, IL-10) and tissue 
repair agents (lipoxins, resolvins) [37,39,81,131].  The neurally-based cholinergic anti-
inflammatory pathway, on the other hand, comprises the centrally-controlled efferent arc of 
the anti-inflammatory reflex.  This involves the fine-tuned, targeted and rapid release of 
acetylcholine into local regions via selected motor branches of the vagus nerve.  The efferent   12 
vagus nerve is able to exert systemic and local anti-inflammatory effects in a ‘real-time’ 
manner, relative to the slower and more diffuse humoral pathway [37-39,81,131].   
Most fibres in the vagus nerve are visceral afferents that supply major organs such as the 
heart, lungs, liver, spleen and gastrointestinal tract.  The remaining 10% - 25% of the vagus 
nerve comprises efferent fibres that not only provide parasympathetic innervation to the 
cardiovascular system, liver, spleen, gut and other visceral organs, but also significantly 
contribute to proper regulation of the cholinergic anti-inflammatory pathway [81,132-134].  
Efferent vagal cholinergic release leads to activation of the α7 subunit of the nicotinic 
acetylcholine receptor expressed by monocytes, macrophages and other cytokine-producing 
cells (mast cells, B cells, T cells, dendritic cells and microglia), and may also act on vascular 
endothelial cells and certain neurons.   
The afferent arc of the anti-inflammatory reflex fulfils a sensory function by detecting 
inflammatory stimuli (e.g., IL-1β) in the periphery via afferent vagal fibres.  This leads to 
glutamate release in the nucleus tractus solitarius (NTS) of the medulla oblongata.  The NTS 
neurons project to numerous central structures involved in pain processing and other 
functions, including brainstem nuclei (locus coeruleus, rostral ventrolateral medulla, 
parabrachial nucleus in the pons, nucleus raphe magnus), central nucleus of the amygdala, 
paraventricular nucleus in the hypothalamus, insular cortex, anterior cingulate cortex and 
medial prefrontal cortex.  The NTS neurons also project via the medial lemniscus to the 
ventral posterior medial nucleus of the thalamus, and then to the somatosensory cortex in the 
parietal lobe (parietal superior operculum).  Afferent vagal fibres in the NTS project to, and 
form synapses with, the central terminals of efferent vagal fibres in the dorsal motor nucleus 
and nucleus ambiguus.  Thus, the NTS is a major intersection for afferent and efferent vagal 
fibres involved in immunomodulation.  This neuroanatomical configuration enables the 
efferent arc of the anti-inflammatory reflex to act reflexively and in a precise manner   13 
following central processing of noxious inflammatory stimuli detected by afferent vagal 
fibres in the periphery [37-39,81,134-136].   
Efferent vagal fibres, immune cells (B cells, T cells, dendritic cells, neutrophils), 
keratinocytes and vascular endothelial cells all release acetylcholine [37-39,137,138]. 
Transient exposure to acetylcholine results in α7-mediated JAK2/STAT3 activation that 
prevents the translocation of NFκB from the cytoplasm into the nucleus.  This leads to 
suppression of pro-inflammatory cytokine production by macrophages and other immune 
cells, without altering the anti-inflammatory cytokine profile (IL-10, corticosterone, 
transforming growth factor-β) [16,37-39,81,131,139,140].  Conversely, disruption of the 
efferent arc of the anti-inflammatory reflex may lead to decreased vagal cholinergic outflow 
and increased pro-inflammatory cytokine production by activated immune cells (Figure 2).  If 
left unchecked, this could result in persistent and exaggerated ‘sterile’ inflammation, tissue 
injury and necrotic cell death.   
As the efferent vagus nerve does not directly innervate the limbs, exactly how the cholinergic 
anti-inflammatory pathway is able to control inflammation at distal sites is not clear.  
Nonetheless, in animals with experimentally-induced paw inflammation, vagal nerve 
stimulation inhibits foot-pad edema [141].  Acetylcholine released from endothelial cells 
regulates leukocyte trafficking via modulation of adhesion molecule expression [37-39]. 
Cholinergic agonist-induced activation of the α7 subunit inhibits TNF-induced adhesion 
molecule expression in human microvascular endothelial cells, hence blocking monocyte and 
neutrophil adhesion to these cells.  This decreases recruitment, extravasation and migration of 
circulating leukocytes into localized inflamed tissue sites and reduces local TNF production 
[138,142-144].  Similarly, electrical stimulation of the vagus nerve decreases the activity of 
circulating dendritic cells and monocytes that release TNF, IL-6 and IL-12 [145].     14 
The efferent vagus nerve targets the spleen via the splenic nerve to modulate both systemic 
and localized inflammation [38].  The splenic nerve may deliver specific anti-inflammatory 
signals that modify circulating neutrophils, monocytes and lymphocytes as they pass through 
the spleen.  Once altered, these circulating white blood cells might then migrate to distal 
inflamed sites where they exert anti-inflammatory effects.  Alternatively, circulating immune 
cells may no longer be chemo-attracted to distal inflamed regions due to vagally-altered 
down-regulation of relevant receptors during their transit through the spleen [81,132].   
Disruption of the cholinergic anti-inflammatory pathway might contribute to symptoms of 
CRPS. In support of this possibility, Kohr et al. [146] reported that the serum from a subset of 
CRPS patients contained surface-binding autoantibodies against autonomic neurons.  In 
particular, autoantibody binding to primary cultured autonomic neurons was detected in 13 of 
30 (43.3%) CRPS patients.  Furthermore, an inducible surface cholinergic antigen in 
differentiated SH-SY5Y neuroblastoma cells was recognized by the sera of 18 of 30 CRPS 
patients [146].  Recent work suggests that autoantibodies in CRPS form a functionally-active 
subclass of immunoglobulin G, and that the antigens for these agonistic autoantibodies are 
contained within the second extracellular loop of muscarinic-2 receptors and β2-
adrenoceptors [147].  Muscarinic M2 receptor agonists may decrease neurogenic 
inflammation and desensitize nociceptors [148].  In addition, however, central muscarinic 
acetylcholine receptors play an important role in the activation of the cholinergic anti-
inflammatory pathway.  In particular, acetylcholine is negatively regulated by the presynaptic 
M2 autoreceptor in several brain regions.  Activation of the M2 autoreceptor (by 
acetylcholine or other cholinergic agonists) can lead to reduced acetylcholine release in the 
synaptic cleft in the central terminal of the efferent vagus nerve, leading to decreased central 
cholinergic neurotransmission and reduced vagal output [149].  As such, agonistic 
autoantibodies to muscarinic-2 acetylcholine receptors could disrupt vagal outflow in CRPS.    15 
Importantly, significant pain relief was obtained by 3 of 12 CRPS patients following 
intravenous immunoglobulin treatment to neutralize serum autoantibodies [150] (see below 
and Table 1).  Further research is warranted to clarify the role of autoantibodies in CRPS.  
Effect of the cholinergic anti-inflammatory pathway on TNF 
The cholinergic anti-inflammatory pathway has been explored extensively in animal models 
involving ischemia-reperfusion injury and hemorrhagic (circulatory) shock.  For example, 
aortic occlusion restricted blood flow and mediated an exaggerated innate immune response 
with excess cytokine release.  Conversely, vagal nerve stimulation before or after aortic 
occlusion inhibited the cytokine response [37-39,151].  Similarly, vagal nerve stimulation 
reversed hypotension, inhibited NFκB signaling and reduced TNF production in a model that 
involved clamping the splanchnic arteries for 45 minutes [152].  In a bilateral renal ischemia-
reperfusion injury model, pretreatment with nicotine or a selective α7 agonist reduced renal 
dysfunction and tubular necrosis via decreased TNF production [153].  Finally, vagal outflow 
provided protection against hemorrhagic (circulatory) shock, likely via decreased 
translocation of NFκB into the cell nucleus, reduced TNF synthesis, and decreased 
hypotension [37-39,154,155].  
At present, little is known about the effects of vagal nerve stimulation on hyperalgesia in 
animal models of neuropathic pain. It may be useful to explore this further, as findings could 
have important implications for CRPS.        
Is TNF a useful target for treating CRPS? 
A range of clinical and experimental evidence suggests that anti-inflammatory drug 
treatments (e.g., corticosteroids) alleviate CRPS by reducing TNF and other inflammatory 
mediators [15,17,18,50].  Infliximab selectively targets TNF, similar to other TNF 
monoclonal antibodies (adalimumab, certolizumab pegol, afelimomab and golimumab).   16 
Other drugs not widely appreciated for their anti-inflammatory effects but that nonetheless 
have demonstrated treatment benefits in CRPS include intravenous immunoglobulin, 
pregabalin (and gabapentin), thalidomide (and its newer generation derivative lenalidomide), 
memantine, N-acetylcysteine and bisphosphonate drugs (pamidronate, ibandronate, 
clodronate, alendronate).  Representative examples of treatment studies are listed in Table 1 
and described below. 
Infliximab has been used to treat lumbar radicular pain including severe sciatica [156-160] 
and rheumatoid arthritis [161]. Analysis of blister fluid from CRPS-affected limbs of two 
patients indicated that local concentrations of TNF and IL-6 were significantly decreased 
following selective anti-TNF (infliximab) treatment.  This was accompanied by amelioration 
of pain, vascular disturbances, edema, motor dysfunction and other symptoms [162].  In 
addition, a patient with acute CRPS type 1 showed near complete remission following 
infliximab treatment for eight weeks [163].  Furthermore, a controlled trial involving 13 
CRPS type 1 patients showed positive results for the infliximab-treated patients (n=7) 
compared with the placebo group (n=6) (Nederlands Trial Register 449 ISRCTN 75765780).  
Corticosteroid treatment inhibits local inflammation and reduces serum TNF [17].  In a 
randomized controlled trial that compared corticosteroid (oral prednisolone) to NSAID (oral 
piroxicam) treatment for up to one month in 60 CRPS patients following stroke, symptoms 
improved significantly in 25 of the 30 patients who received prednisolone compared with 
only 5 of the 30 patients in the piroxicam control group [164].  Lasting therapeutic results, 
including significant pain relief, were reported in other controlled trials and numerous case 
series following corticosteroid therapy [93,165-175].  Thus, further research involving 
corticosteroid and other anti-inflammatory (TNF-inhibiting) drug treatments for CRPS 
appears warranted [176].    17 
Intravenous immunoglobulin not only inhibits certain autoantibodies but may also reduce 
pro-inflammatory cytokine levels [177] and exert potent anti-inflammatory activity [178].  In 
particular, intravenous immunoglobulin treatment may result in saturation of macrophage Fc 
receptors, suppression of pro-inflammatory mediators (TNF, macrophage colony-stimulating 
factor and monocyte chemoattractant protein-1), up-regulation of anti-inflammatory 
cytokines and inhibition of endothelial cell activation and inflammation [179-184]. This 
treatment was recently reported to decrease immune activation, reduce pain and improve 
autonomic disturbances in patients with CRPS [150].     
Pregabalin (and gabapentin) is approved for treatment of post herpetic neuralgia and painful 
diabetic peripheral neuropathy, and may also be prescribed ‘off-label’ for CRPS and other 
neuropathic pain conditions.  Varying degrees of success with this drug have been reported 
for CRPS [185-189].  Pregabalin (and gabapentin) bind with the α2δ1 calcium 
channel subunit, leading to inhibition of translocation of NFκB into the cell nucleus and 
reduced gene transcription for inflammatory agents including IL-6 [190,191] and (likely) 
TNF.   
Thalidomide offers various degrees of relief in CRPS patients [192-198].  Lenalidomide, an 
analogue with greater potency and less toxicity, also extends certain benefits for some CRPS 
patients.  Specifically, 14 of 40 CRPS patients who took oral lenalidomide treatment for more 
than 2 years showed overall improvement in symptoms including improvements in pain, 
allodynia and sleep [199].  An earlier study reported similar results following 12-week 
lenalidomide treatment [200].  The therapeutic effects may be mediated by degradation of 
TNF mRNA [50].  Thalidomide also inhibits TNF-induced NFκB activation, hence 
preventing further TNF synthesis [201,202].  Due to known risks of severe teratogenicity, 
availability of thalidomide is limited to patients beyond child-bearing age.   18 
Promising results have also been reported for memantine and memantine/morphine treatment 
in CRPS patients.  Specifically, pain decreased in three CRPS patients following 8-week oral 
memantine treatment [203] and in six CRPS patients in a follow-up study [204].  More 
recently, 10 CRPS patients benefited significantly following memantine/morphine 
combination treatment [205].  As administration of memantine hydrochloride decreases TNF 
expression in animals [206], studies are warranted to determine whether memantine decreases 
local TNF in CRPS patients (in addition to effects on NMDA and other receptors). N-
acetylcysteine may also benefit certain ‘cold’ CRPS type 1 patients [207] by inhibiting NFκB 
translocation and reducing TNF production [41,43]. 
Bisphosphonate treatment evokes apoptosis of macrophages and macrophage-derived 
osteoclasts, and decreases production of TNF and other inflammatory mediators in vitro and 
in vivo [208-213].  A pilot study involving ibandronate (a third generation amino-
bisphosphonate) indicated that pain ratings decreased in patients with upper limb CRPS 
[214].  Numerous studies involving bisphosphonates, including pamidronate, clodronate and 
alendronate treatment, have demonstrated varying degrees of success in CRPS patients 
[198,215-232].   
Together, the findings reviewed above suggest that drugs that reduce the availability of TNF 
and other inflammatory cytokines contribute significantly to the amelioration of pain and 
‘sterile’ inflammation in CRPS. As such, the ability to block TNF may play a key role in the 
treatment of pain and edema in CRPS.  It is noteworthy that complete remission from CRPS 
was reported in small subset of patients following TNF-inhibiting drug treatment (Table 1).   
Although effective in some cases, drug treatments that target TNF may increase the risk of 
secondary infections or other adverse events.  Hence, it is important to establish whether 
prolonged stimulation of the cholinergic anti-inflammatory pathway decreases TNF 
production and ameliorates symptoms in CRPS. Non-invasive techniques that increase vagal   19 
outflow include acupuncture, controlled deep breathing (via deep breathing exercises, yoga, 
Tai Chi, Qigong) and meditation [81,122,233-235].  Benefits of diaphragmatic breathing 
exercises, mental imagery, music therapy, hydrotherapy, proprioception training, tactile 
desensitisation (for allodynia), physical/gym rehabilitation, recreational/socialisation therapy, 
massage, relaxation (for stress management) and problem solving/assertiveness training have 
been reported for children with CRPS [236]. Whether these treatment gains involve increased 
vagal outflow or reductions in TNF is unknown. 
Conclusions 
Increased local production of TNF may contribute to the onset and maintenance of CRPS by 
promoting chronic ‘sterile’ inflammation and secondary microvascular disturbances including 
impaired sympathetic cutaneous vasoconstriction.  Thus, it may be desirable to reduce local 
TNF levels by means of selective anti-TNF drug treatment or via pharmacological, electrical 
or non-invasive stimulation of the cholinergic anti-inflammatory pathway. From an 
experimental and clinical perspective, research into anti-TNF therapy may offer additional 
insights into the pathogenesis of CRPS, and result in the development of cost-effective 
treatment options for this devastating disease.  
   20 
References 
 
1.  Jänig W, Baron R. Complex regional pain syndrome is a disease of the central nervous 
system. Clin Auton Res 2002; 12: 150-64. 
2.  Jänig W, Baron R. Complex regional pain syndrome: mystery explained? Lancet 
Neurol 2003; 2: 687-97. 
3.  de Mos M, Sturkenboom MCJM, Huygen, FJPM. Current understandings on complex 
regional pain syndrome. Pain Practice 2009; 9: 86-99. 
4.  Coderre TJ, Bennett GJ. A hypothesis for the cause of complex regional pain 
syndrome-type I (reflex sympathetic dystrophy): pain due to deep-tissue microvascular 
pathology. Pain Med 2010; 11: 1224–38. 
5.  Jänig W. The fascination of complex regional pain syndrome. Exp Neurol 2010; 221: 1-
4. 
6.  Maihöfner CF, Seifert F, Markovic K. Complex regional pain syndromes: new 
pathophysiological concepts and therapies. Eur J Neurol 2010; 17: 649–60. 
7.  Naleschinski D, Baron R. Complex regional pain syndrome type I: neuropathic or not? 
Curr Pain Headache Rep 2010; 14: 196-202.   
8.  Harden RN. Objectification of the diagnostic criteria for CRPS. Pain Med 2010; 11: 
1212–5. 
9.  Bruehl S. An update on the pathophysiology of complex regional pain syndrome. 
Anesthesiology 2010; 113: 713-25. 
10.  Marinus J, Moseley GL, Birklein F, Baron R, Maihöfner C, Kingery WS, van Hilten JJ. 
Clinical features and pathophysiology of complex regional pain syndrome. Lancet 
Neurol 2011; 10: 637-48. 
11.  Wasner G, Schattschneider J, Binder A, Baron R. Complex regional pain syndrome - 
diagnostic, mechanisms, CNS involvement and therapy. Spinal Cord, 2003; 41: 61-75.   21 
12.  de Mos M, Huygen FJ, Dieleman JP, Koopman JS, Stricker BH, Sturkenboom MC. 
Medical history and the onset of complex regional pain syndrome (CRPS). Pain 2008; 
139: 458–66. 
13.  Groeneweg G, Huygen FJPM, Coderre TJ, Zijlstra FJ. Regulation of peripheral blood 
flow in complex regional pain syndrome: clinical implication for symptomatic relief 
and pain management. BMC Musculoskelet Disord 2009; 10: 116. 
14.  Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. 
Brain Res Rev 2006; 51: 240-64. 
15.  Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat 
Rev Neurosci 2005; 6: 521–32. 
16.  Zwergal A, Quirling M, Saugel B, Huth KC, Sydlik C, Poli V, Neumeier D, Ziegler-
Heitbrock HW, Brand K. C/EBPβ blocks p65 phosphorylation and thereby NF-κB-
mediated transcription in TNF-tolerant cells. J Immunol 2006; 177; 665-72. 
17.  Krämer HH, Eberle T, Üçeyler N, Wagner I, Klonschinsky T, Müller LP, Sommer C, 
Birklein F. TNF-alpha in CRPS and ‘normal’ trauma – significant differences between 
tissue and serum. Pain 2010 (in press).  
18.  Leung L, Cahill CM. TNF-α and neuropathic pain - a review. J Neuroinflamm 2010; 7: 
27. 
19.  Cunha TM, Verri WA, Valerio DA, Guerrero AT, Nogueira LG, Vieira SM, Souza DG, 
Teixeira MM, Poole S, Ferreira SH, Cunha FQ. Role of cytokines in mediating 
mechanical hypernociception in a model of delayed-type hypersensitivity in mice. Eur J 
Pain 2008; 12: 1059-68.   
20.  Parada CA, Yeh JJ, Joseph EK, Levine JD. Tumor necrosis factor receptor type-1 in 
sensory neurons contributes to induction of chronic enhancement of inflammatory 
hyperalgesia in rat. Eur J Neurosci 2003; 17: 1847-52.   22 
21.  Schäfers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-α induces 
mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary 
sensory neurons. J Neurosci 2003; 23: 2517-21. 
22.  Svensson CI, Schäfers M, Jones TL, Powell H, Sorkin LS. Spinal blockade of TNF 
blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett 2005; 379: 
209-13. 
23.  Jin X, Gereau RW. Acute p38-mediated modulation of tetrodotoxin-resistant sodium 
channels in mouse sensory neurons by tumor necrosis factor-α. J Neurosci 2006; 26: 
246–55. 
24.  Dussor G. Changes in undamaged fibers following peripheral nerve injury: a role for 
TNF-alpha. Pain 2010; 151: 237-8. 
25.  He X-H, Zang Y, Chen X, Pang R-P, Xu J-T, Zhou X, Wei X-H, Li Y-Y, Xin W-J, Qin 
Z-H, Liu X-G. TNF-α contributes to up-regulation of Nav1.3 and Nav1.8 in DRG 
neurons following motor fiber injury. Pain 2010; 151: 266-79.  
26.  Ibeakanma C, Vanner S. TNFα is a key mediator of the pronociceptive effects of 
mucosal supernatant from human ulcerative colitis on colonic DRG neurons. Gut 2010; 
59: 612-21. 
27.  Sabsovich I, Guo TZ, Wei T, Zhao R, Li X, Clark DJ, Geis C, Sommer C, Kingery WS. 
TNF signaling contributes to the development of nociceptive sensitization in a tibia 
fracture model of complex regional pain syndrome type I. Pain 2008; 137: 507-19.   
28.  Li WW, Sabsovich I, Guo TZ, Zhao R, Kingery WS, Clark JD. The role of enhanced 
cutaneous IL-1beta signaling in a rat tibia fracture model of complex regional pain 
syndrome. Pain 2009; 144: 303-13. 
29.  Kingery WS. Role of neuropeptide, cytokine, and growth factor signaling in complex 
regional pain syndrome. Pain Med 2010; 11: 1239–50.    23 
30.  Li WW, Guo TZ, Li XQ, Kingery WS, Clark JD. Fracture induces keratinocyte 
activation, proliferation, and expression of pro-nociceptive inflammatory mediators. 
Pain 2010; 151: 843-52. 
31.  Kingery W, Li W, Guo T, Liang D, Clark J. Substance P signaling controls mast cell 
activation, degranulation, IL-1 cytokine expression, and nociceptive sensitization in a 
rat fracture model of complex regional pain syndrome. IASP (Montreal) 2010, PM 193. 
32.  Wei T, Sabsovich I, Guo TZ, Shi X, Zhao R, Li W, Geis C, Sommer C, Kingery WS, 
Clark DJ. Pentoxifylline attenuates nociceptive sensitization and cytokine expression in 
a tibia fracture rat model of complex regional pain syndrome. Eur J Pain 2009; 13: 253-
62.    
33.  Coderre TJ, Xanthos DN, Francis L, Bennett GJ. Chronic post-ischemia pain (CPIP): a 
novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex 
sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in 
the rat. Pain 2004; 112: 94–105. 
34.  de Mos M, Laferrière A, Millecamps M, Pilkington M, Sturkenboom MC, Huygen FJ, 
Coderre TJ. Role of NFκB in an animal model of complex regional pain syndrome–type 
I (CRPS-I). J Pain 2009; 10: 1161-9. 
35.  Coderre TJ. An animal model suggests microvascular dysfunction and chronic tissue 
ischemia contribute to CRPS-1. Eur J Pain Suppl 2010; 4: 8. 
36.  Tegeder I, Niederberger E, Schmidt R, Kunz S, Guhring H, Ritzeler O, Michaelis M, 
Geisslinger G. Specific inhibition of IκB kinase reduces hyperalgesia in inflammatory 
and neuropathic pain models in rats. J Neurosci 2004; 24: 1637–45. 
37.  Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. J Intern Med 2009; 
265: 663-79.    24 
38.  Rosas-Ballina M, Tracey KJ. The neurology of the immune system: neural reflexes 
regulate immunity. Neuron 2009; 64: 28-32. 
39.  Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009; 9: 418-28. 
40.  Rajan S, Ye J, Bai S, Huang F, Guo Y-L. NF-κB, but not p38 MAP kinase, is required 
for TNF-α-induced expression of cell adhesion molecules in endothelial cells. J Cell 
Biochem 2008; 105; 477–86. 
41.  Kim H, Seo JY, Roh KH, Lim JW, Kim KH. Suppression of NF-κB activation and 
cytokine production by N-acetylcysteine in pancreatic acinar cells. Free Radical Biol 
Med 2000; 29: 674-683.  
42.  Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Caputi AP, Thiemermann C. 
Tempol reduces the activation of nuclear factor- κB in acute inflammation. Free Radic 
Res 2004; 38: 813-9. 
43.  Chen G, Shi J, Hu Z, Hang C. Inhibitory effect on cerebral inflammatory response 
following traumatic brain injury in rats: a potential neuroprotective mechanism of N-
acetylcysteine. Mediat Inflamm 2008; 2008: 716458. 
44.  Laferrière A, Millecamps M, Xanthos DN, Xiao WH, Siau C, de Mos M, Sachot C, 
Ragavendran JV, Huygen FJ, Bennett GJ, Coderre TJ. Cutaneous tactile allodynia 
associated with microvascular dysfunction in muscle. Mol Pain 2008; 4: 49. 
45.  Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is 
dependent on the TNF receptor 1. Exp Neurol 1998; 151: 138-42. 
46.  Sommer C, Lindenlaub T, Teuteberg P, Schäfers M, Hartung T, Toyka KV. Anti-TNF-
neutralizing antibodies reduce pain-related behavior in two different mouse models of 
painful mononeuropathy. Brain Res 2001; 913: 86-9. 
47.  Birklein F, Schmelz M. Neuropeptides, neurogenic inflammation and complex regional 
pain syndrome (CRPS). Neurosci Lett 2008; 437: 199-202.   25 
48.  Sommer C, Schäfers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in 
experimental painful neuropathy. J Periph Nerv Sys 2001; 6: 67-72. 
49.  Marchand F, Tsantoulas C, Singh D, Grist J, Clark AK, Bradbury EJ, McMahon SB. 
Effects of etanercept and minocycline in a rat model of spinal cord injury. Eur J Pain 
2009; 13: 673-81. 
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Figure legends 
Figure 1. Effects of an over-supply of TNF on symptoms of CRPS. The blue arrows represent 
pathways for the prolonged manufacture of TNF and other inflammatory mediators, and for 
the production of symptoms. A deficit in sympathetic vasoconstrictor regulation that results 
in microcirculatory ischaemia and hypoxia may augment necrosis in local tissues (red 
arrows). Inhibition of N-type calcium channel currents in sympathetic vasoconstrictor fibres 
(orange arrows) could further aggravate this cycle. 
Figure 2. The cholinergic anti-inflammatory pathway. Under normal conditions, 
inflammatory mediators detected by vagal afferent fibres activate vagal efferent fibres with 
cell bodies in the dorsal motor nucleus and nucleus ambiguus. This prevents the production 
of TNF (blue arrows). However, failure of this inhibitory process could contribute to 
heightened production of TNF and “sterile” inflammation (red arrows).   48 
Table 1. Drug trials that target an action of TNF (and other primary mechanisms) in CRPS * 
  Diagnosis   Design  Intervention  
 
N   Patient details including age, 
gender, duration of painful 
CRPS and inciting event  
Results including the number of patients 
that benefited from intervention via 
reduced pain and other clinical benefits  
Infliximab (a therapeutic monoclonal antibody that selectively targets TNF) 
Huygen et al. 
[162]  
CRPS type 
1 
Case reports  Infliximab 
 
2  
 
 
Case 1: F, 50  
Spontaneous onset of CRPS 
in left leg 5 years earlier, 
followed by CRPS in right 
leg 2 years later. 
 
Case 2: F, 55 
Acute CRPS caused by a left 
Colles’ fracture 2 months 
earlier (resulting in affected 
limb being casted for 2 
months). 
Infliximab treatment of <1 month led to 
decreased localized TNF and IL-6 in 
blister fluid.  Amelioration of CRPS 
symptoms including pain, temperature, 
edema and motor dysfunction occurred in 
both patients. 
Bernateck et al. 
[163]   
 
CRPS type 
1 
Case report  Infliximab  
 
1   
 
F, 62. Acute CRPS caused by 
a left Colles’ fracture 3 
months earlier. 
Near complete remission following 
infliximab treatment for 8 weeks. 
Trial Register 449 
ISRCTN 
75765780 
CRPS type 
1 
Controlled 
trial 
Infliximab (n=7) 
Placebo (n=6) 
7  Aged 18 - 65  Positive results for infliximab-treated 
patients, compared to placebo group. 
** Corticosteroids (corticosteroid treatment inhibits local inflammation and serum TNF [15])    49 
Wasner et al. [93]  
 
 
 
CRPS type 
1 
Case report  Treatment also 
included 
sympatholytic 
blocks, NSAIDs and 
physiotherapy for 6 
weeks. 
1  
 
 
F, 52. Acute CRPS in right 
forearm and hand (following 
right distal radius fracture 
and plaster). 
Full recovery from CRPS within one year, 
post fracture.   
 
 
Kalita et al. [164] 
 
 
Patients 
who 
developed 
CRPS 
after 
stroke 
Randomized 
controlled 
trial 
Corticosteroids 
(prednisolone) for up 
to one month (n=30). 
Control patients 
received NSAID 
(piroxican) (n=30). 
Both groups 
underwent ongoing 
physiotherapy. 
60   CRPS developed within 7 to 
100 days following stroke in 
all 60 patients (40 males, 20 
females; 40 - 70 years; mean 
age=56) 
 
25/30 (83.3%) CRPS patients benefited 
significantly from daily corticosteroid 
(oral prednisolone) treatment, compared 
with 5 of 30 (16.7%) CRPS patients 
following NSAID (piroxican) treatment. 
Bianchi et al. 
[166] 
 
CRPS  Case reports  Corticosteroids 
(prednisone) 
25  
 
  
Various   21 of 25 CRPS patients derived lasting 
benefits following corticosteroid 
treatment. 
Braus et al. [167]  
 
 
Shoulder-
hand 
syndrome 
after 
stroke in 
hemiplegic 
patients 
Randomized 
placebo-
controlled 
non blinded 
trial 
Corticosteroids (oral 
methylprednisolone) 
36   Various  31 patients became ‘almost symptom 
free’ following daily low doses of 
corticosteroids (oral methylprednisolone) 
for up to 10 days. 
Kozin et al. [168] 
 
RSD  Comparative 
non-
randomized 
Comparison of 
systemic oral 
prednisone (n=35) to 
stellate ganglion 
55   
  
Various  Prednisone treatment resulted in 
‘excellent’ results for 14 patients (40%) 
and ‘good’ results for 8 patients (23%).  
However, 17 patients had ‘poor’ results   50 
  study  blockade (n=20)  and 3 patients had only ‘fair’ results 
following stellate ganglion blocks (n=20).   
Grundberg [169] 
 
 
RSD  Case reports  Corticosteroids 
(methylprednisolone 
injections) 
69   Various  47 of 69 patients obtained significant 
benefits. 
Christensen et al. 
[165] 
 
 
Acute 
RSD  
Randomized 
placebo-
controlled 
trial 
Corticosteroids 
(oral prednisone for 
a maximum of 12 
weeks) (n=13). 
Placebo (n=10). 
23  
 
 
22/23 had sustained a fracture 
while 1 had an abscess 
following an incision. 
Mean duration from trauma 
to RSD diagnosis was 92 
days (range 50-194 days). 
All 13 patients in the prednisone 
treatment group showed greater than 75% 
clinical improvement within 12 weeks. 
 
  
Glick [170] 
 
 
RSD 
(acute and 
chronic) 
Case reports  Corticosteroids  
 
17   RSD caused by elbow injury 
(n=4), post surgery (n=3), 
wrist fracture (n=1), finger 
injury (n=1), leg injury (n=1) 
and shoulder-hand syndrome 
(n=7).  
12 of 17 RSD patients had fair to 
excellent results following daily 
corticosteroid treatment for 10-70 weeks. 
Glick & Helal 
[171] 
 
 
Post-
traumatic 
neuro-
dystrophy 
Case reports  All patients were 
given daily oral 
prednisolone for 6-8 
8 months except for 
2 patients who 
received 
intramuscular 
methylprednisolone  
21  Various  10 had ‘very good’ results (pain relief and 
good movement) and 3 had ‘good’ results 
(limited pain requiring nil analgesics and 
some movement). 
Zyluk [172] 
 
 
Painful 
RSD of 
upper limb 
Case reports  A solution of 
methylprednisolone, 
lidocaine and 
heparin was injected 
36  23 females; 13 males; 44-73 
years. RSD-inciting events 
included distal radius fracture 
(n=22), fasciectomy (n=5) 
At 1-year follow-up, 25 patients (69%) 
reported ‘good’ relief of spontaneous pain 
and normal finger movements.    51 
into the dorsal side 
of the affected hand 
or wrist, and a 20-25 
minute occlusion 
block was 
maintained.   
and other hand injuries (n=9). 
RSD duration was less than 1 
year in all cases.  
Poplawski et al. 
[173] 
 
 
Post-
traumatic 
dystrophy 
of the 
extremities 
Case reports  Regional IV blocks 
involving a solution 
of corticosteroid 
(methylprednisolone 
and lidocaine for 
~30 minutes) 
27  13 males; 14 females; aged 
31- 81 years. Duration ranged 
from 2-36 months 
 
   
10 patients (11 limbs) had ‘excellent’ 
results that included little or no pain and 
edema as well as a full range of motion. 
Five patients obtained ‘good’ or ‘very 
good’ results, and required nil or 
infrequent analgesia.  
Tountas & 
Noguchi [174]  
 
 
RSD  Case reports  Regional IV blocks 
involving a solution 
of corticosteroid 
(methylprednisolone 
sodium succinate) 
and lidocaine  
17  Inciting event included distal 
radius fracture 
 
Duration ranged from 2 days 
to almost 6 months. 
At 6 months, 11 patients showed 
complete or almost complete relief from 
symptoms.   
Zyluk & 
Puchalski [175] 
Acute 
CRPS type 
1 
Case reports  Mannitol and 
dexamethasone 
combination 
treatment (daily for 
1 week) 
75  75 patients (68 females; 7 
males; aged 38-82; Duration 
less than 4 months. Various 
inciting events. 
After 1-week treatment, pain from a mean 
Visual Analogue Scale (VAS) dropped 
from 6.7 to 2.3. 
 
After 8-12 months, at the final 
assessment, 70 patients had a mean VAS 
of 1.8.  Other variables also improved 
significantly. 
Thalidomide or lenalidomide (these agents act intracellularly, resulting in inhibited production of TNF and other cytokines) [193,194] 
Rajkumar et al. 
[192,196] 
RSD  Case report  Thalidomide   1  
 
F, 43 
3 years duration. 
After 1-month thalidomide treatment RSD 
was almost entirely resolved, and the leg   52 
 
 
Caused by traumatic injury to 
her left hand. 
ulcer and edema were completely healed.  
The patient no longer needed her 
wheelchair and walked normally.  She no 
longer took pain medication and regained 
function in her left hand several months 
later.  When the patient was followed up 
30 months later, she remained free of 
CRPS. 
Schwartzman et 
al. [197] 
 
 
CRPS  Case reports  Thalidomide  
 
42   
 
 
Long-standing CRPS disease.  7  (17%) patients showed a ‘dramatic 
response’ following thalidomide 
treatment, while 6 (14%) patients had 
‘modest pain relief’ and/or reduced their 
pain medication. 
Ching et al. [194]  
 
CRPS type 
1 
Case report  Thalidomide   1   
 
F, 33. CRPS caused by a fall 
on left knee 6 years earlier 
CRPS pain in her left knee disappeared, 
post thalidomide treatment. 
Bengtson et al. 
[193] 
 
Chronic 
upper limb 
CRPS 
Phase II trial  Thalidomide   12   
 
CRPS duration exceeded 1 
year in all patients  
Thalidomide treatment for 6 months 
resulted in significant pain reduction in 4 
patients. 
Prager et al. [195]  
 
CRPS type 
1 
Case reports   Thalidomide  
 
9  2 males, 7 females  Pain decreased significantly in 7 of 9 
patients after thalidomide treatment. 
  
Manning [199] 
 
 
CRPS type 
1 
Case reports  Lenalidomide  
 
40  
 
 
Genders/ages not specified  14 of 40 patients took oral lenalidomide 
treatment for >2 years.  These patients 
showed overall improvement in 
symptoms including improvements in 
pain, allodynia and sleep. 
Schwartzman et 
al. [200] 
Chronic 
CRPS type 
Case reports  Lenalidomide.  
Multicenter (6 
40   Average duration 6 years, 
75% female 
Daily oral lenalidomide treatment resulted 
in sustained symptom reduction including   53 
 
 
1   
 
centers), open label, 
12-week study (the 
core phase), plus 
option to extend for 
a further 40 weeks 
pain reduction in all 31 patients that 
completed the core phase. 18 (of 31) also 
completed the extended 40-week period 
(and continued into 2
nd year of treatment. 
Intravenous immunoglobulin (macrophage Fc receptor inhibition may suppress TNF production and reduce endothelial cell activation [174], and also 
neutralize autoantibody effects in some autoimmune diseases [176]) 
Goebel et al. [150]  
 
 
CRPS  Randomized, 
double-blind, 
placebo-
controlled 
crossover 
trial 
Intravenous 
immunoglobulin  
 
13   
  
 
 
6 to 30 months duration. 
Various inciting events 
3 of 12 CRPS patients who completed the 
trial had significant pain relief following 
intravenous immunoglobulin therapy.  
 
Gabapentin and pregabalin (bind with the α2δ1 calcium channel subunit. In addition to decreased neurotransmitter release, this may inhibit translocation 
of NFκB into the cell nucleus and decrease the production of inflammatory agents including TNF [34,38,182,183]) 
Mellick & Mellick 
[187] 
 
RSD  Case reports  Gabapentin 
 
   
6  
 
42-68 years, all female. 
Various durations/ inciting 
events  
Pain reduction ranged from 85% to 100% 
in 5 patients and 60% in the other patient. 
Wheeler et al. 
[188] 
 
Childhood 
RSD 
(acute) 
Case report  Gabapentin 
 
1   Girl, 9 years. Inciting event: 
ingrown nail with purulent 
drainage in left big toe 
Complete resolution of all CRPS 
symptoms following gabapentin 
treatment. 
Memantine (in addition to effects on NMDA and other receptors/channels [195,196,197], memantine may decrease TNF expression [198]) 
Sinis et al. [203] 
 
 
CRPS  Case reports  Oral memantine for 
8 weeks  
  
3   
 
F, 60; M, 58; M, 49. CRPS 
duration 1-7 months; various 
trauma-inciting events 
Nil ‘resting’ pain was present in 3 patients 
at the 6 month follow-up.   54 
Sinis et al. [204]  
 
 
CRPS  Case reports  Memantine  6   
 
4 men and 2 women (29-64 
years; mean age 48.3 years). 
CRPS duration: 4-23 months; 
various trauma-inciting 
events 
Pain decreased significantly and 
‘continuous’ pain was abolished in 6 
patients after 8 weeks of memantine 
treatment (as reported at the 6 month 
follow-up). This was accompanied by an 
improvement in motor symptoms and 
autonomic changes in all patients. 
Gustin et al. [205] 
 
 
CRPS  Double-blind 
randomized 
placebo-
controlled 
study 
Memantine + 
morphine (n=10) 
 
Placebo + morphine 
(n=10) 
20  
 
 
8 men and 12 women; 29-69 
years; mean age 50.9 years. 
CRPS duration 6-36 months; 
various trauma-inciting 
events 
Pain decreased significantly in 10 CRPS 
patients after the memantine/morphine 
combination treatment for 8 weeks. 
 
N-acetylcysteine (a free radical scavenger [199] that may also inhibit NFκB and cytokine production including TNF [39,41]) 
Perez et al. [207]  
 
 
CRPS type 
1 
 
Randomized 
actively 
controlled 
trial 
CRPS patients were 
randomly assigned 
to either N-
acetylcysteine 
(n=74) or DMSO 
(n=71) for 17 weeks 
(regardless whether 
they were ‘warm’ or 
‘cold’ CRPS). 
74  20 males; 54 females; mean 
age 48.94 years; 18 ‘cold’ 
CRPS patients and 56 ‘warm’ 
CRPS patients. Median 
duration of CRPS pain: 102 
days. 
 
 
The 18 ‘cold’ CRPS patients benefited 
from N-acetylcysteine treatment whereas 
the 56 ‘warm’ CRPS patients did not. 
  
 
  
*Bisphosphonate treatment for CRPS may also exert inhibitory effects on TNF production, but these studies are not included in the table. 
**Additional corticosteroid-related studies were reviewed by Fischer et al. [167]. 
 